Introduction: Based on the grim statistics, the mortality of alcoholic liver disease was in last years the high in the undeveloped countries but and in developed countries in the statistic compared with last years.
Aim: Scope of this work was to discover the patients diagnosed with alcoholic cirrhosis which in time was transformed in Hepatocellular Carcinoma, (HCT) by continue abuse alcohol and which presented, at a previous medical control, with the diagnosis of steatohepatitis after the chronic abuse of alcohol.
Methodology: The retrospective study consisted of 180 patients, adult men (mean age 55 years) and females (mean age = 48) hospitalized and investigated for alcoholic liver diseases. From total cases investigated, 54 cases (30% from of cases admitted in hospital, meaning 27 men and 17 women), which were diagnosed with alcoholic liver cirrhosis in last 5-7 years but in next medical controls were discovered liver cancers in the 6.1% percent.
Results: The majority of patients with uncompensated liver cirrhosis, (70%), have had elevated AST in average 66 U/L value, (N= 5-38U/L). Also, they have had an AST/ALT ratio 1.36, (N = 1.33) and ratio TGP/TGO = 0.95. In the liver carcinogenesis process the report AST/ALT increased in 2.64 value and ratio TGP/TGO decreased in 0.67 value.
Conclusions: The active and rational lifestyle is an essential element in preventing the process of carcinogenesis. Liver disease it's not just how much you drink, but how and when you drink. The treatment of severe alcoholic hepatitis will be necessary in all alcoholic liver diseases centers to prevent hepatic cancer disease.
Reddy SR, Mouchli M, Summey R, Walsh C, Mir A, Bierle L, et al. Outcomes of Young Patients With Alcoholic Cirrhosis After First Hospitalization for Cirrhosis: A Carilion Clinic Experience. Cureus. 2021; 13 (7): e16695.
Sandoval JL, Leão T, Theler JM, Favrod-Coune T, Broers B, Gaspoz JM, et al. Alcohol control policies and socioeconomic inequalities in hazardous alcohol consumption: a 22-year cross-sectional study in a Swiss urban population. BMJ Open. 2019; 9: e028971.
Arteel GE. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology. 2003; 124(3): 778–90.
Szabo G, Mandrekar P. Focus On: Alcohol and the Liver. Alcohol and Health. 2010; 33(1/2): 25-33.
Lieber CS. The metabolism of alcohol. Sci Am. 1976; 234(3): 25-33.
Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. Ligue Contre le Cancer. 8 October 2018 1AP-HP. Hôpital Jean Verdier. F-75010 Paris, France.
Guan X, Xing F, Li Y. Alcohol consumption increases the incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis but not in patients with hepatitis C cirrhosis. Eur J Gastroenterol Hepatol. 2021; 33(9): 1218-21.
Szachowicz-Petelska B. Changes in the Lipid Composition of Biological Membranes under the Influence of Endogenous and Exogenous Factors. Biochemistry (Mosc). 2019; 84(2): 164-70.
Anderson P. WHO Reports 3 Million Alcohol-Related Deaths in 2016. Medscape Medical News. [Internet] 2018. [cited 2022 Jan 2] Available from: https://www.medscape.com/viewarticle/902614.
Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med. 2005; 26(4-5): 391-404.
Bala S, Marcos M, Szabo. G. Emerging role of microRNAs in liver diseases. World Journal of Gastroenterology. 2009; 15(45): 5633–40.
Bartel PD. Micro RNAs: Target Recognition and Regulatory Functions. Cell. 2009; 136(2): 215–33.
Sato F, Tsuchiya S, Meltzer JS, Shimizu K. MicroRNAs and epigenetics. FEBS J. 2011; 278(10): 1598-609.
Bala S, Szabo, G. MicroRNA Signature in Alcoholic Liver Disease. International Journal of Hepatology. 2012; 10: 1155-61.
Hong FK, Tian WH, Jaruga ZB. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-x(L) proteins. Oncogene. 2002; 21(1): 32-43.
Wiley J, Ltd S. Molecular Biological Physiological and Clinical Aspects of Melatonin. Journal of Pineal Research. 2015; 59: 178–189.
Hossain MR, Pandey RK, Islam MF, Datar P, Gayam V, Puri P, et al. Acute Isolated Hyperbilirubinemia as a Presentation of Alcoholic Liver Disease: A Case Report and Literature Review. Case Reports in Hepatology. 2018.
Nicholas JL, Kelly BL. Suppression of LPS-induced inflammatory responses in macrophages infected with Leishmania. Journal of Inflammation. 2010; 7: 8.
Vassalli G. Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells. Stem Cells International. 2019; 2019: 390-45
Miranda RC, Pietrzykowski AZ, Tang Y, Sathyan P, Mayfield D, Keshavarzian A, et al. MicroRNAs: master regulators of ethanol abuse and toxicity? Alcohol Clin Exp Res. 2010; 34: 575–87.
Loyd, Dr. Stephen. What are the early signs of liver damage?. [Internet] 2020. [cited 2020 June 11] Available from: journeypure.com.
Frazier HT, Stocker MA, Kershner AN, Marsano LS. Treatment of alcoholic liver disease. Therap Adv Gastroenterol. 2011; (1): 63–81.
Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, et al. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. Journal of Cellular Biochemistry. 2010; (6): 1426-36.
Di Castelnuovo A, Costanzo S, Donati BM, Iacoviello L. Prevention of cardiovascular risk by moderate alcohol consumption: epidemioloic evidence and plausible mechanisms. Internal and Emergency Medicine. 2010; 5(4): 291-97.
Siloși, Boldeanu MV, Andrițoiu A, Cojocaru M, Boldeanu L, Avramescu C. The benefits versus potential side effect of post chemoembolization for hepatocarcinoma. Medico Oncology. 2020; 1(9): 1-9.
Rehm J. The Risks Associated with Alcohol Use and Alcoholism. Alcohol Research & Health. 2007; 34(2): 4-8.
Dinavahi SS, Bazewicz CG, Gowda R, Robertson GP. Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics. Trends Pharmacol Sci. 2019; 40(10): 774-89.